National Comprehensive Cancer Network® (NCCN®) recommendations
Indications:1
KISQALI® (ribociclib) is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy
In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist
KISQALI is not recommended to be used in combination with tamoxifen.
To learn more about the safety profile of KISQALI, visit our portal page here.
For full safety profile information, please refer to the KISQALI Summary of Product Characteristics.
The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 33 leading US cancer centres, providing resources used in more than 190 countries.2
NCCN clinical practice guidelines in oncology (NCCN Guidelines®): Breast cancer
NCCN recommendations for KISQALI in HR+/HER2– recurrent, unresectable or stage IV (M1) breast cancer:3,4
KISQALI is a Category 1-rated CDK4/6i in combination with either AI and fulvestrant3,4
Category 1: Based upon high-level evidence (≥1 randomised Phase III trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the panel) that the intervention is appropriate.4
KISQALI + ET is recommended in eligible patients with HR+/HER2– aBC3,4
ET is defined as AI or fulvestrant.3,4
KISQALI is not recommended to be used in combination with tamoxifen.1
How are the NCCN guidelines developed and updated?5
Recommendations are derived from critical evaluation of evidence, integrated with the clinical expertise and consensus of a multidisciplinary panel of experts and researchers
Panels evaluate the efficacy and toxicity of interventions
Recommendations are agreed upon by panel members
NCCN categories for recommendations are based on the level of clinical evidence available and the degree of consensus within the panel
View the table below to learn more about the NCCN categories of evidence and consensus.
NCCN categories of evidence and consensus4
Category 1 | Based upon high-level evidence (≥1 randomised Phase III trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the panel) that the intervention is appropriate |
Category 2A | Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the panel) that the intervention is appropriate |
Category 2B | Based upon lower-level evidence, there is uniform NCCN consensus (≥50%, but <85% support of the panel) that the intervention is appropriate |
Category 3 | Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate |
1L, first-line; aBC, advanced breast cancer; AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; HER2–, human epidermal growth receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinising hormone-releasing hormone; NCCN, National Comprehensive Cancer Network; US, United States.
References:
KISQALI® (ribociclib) Summary of Product Characteristics.
National Comprehensive Cancer Network. Home page. Available at: https://www.nccn.org/ [Accessed March 2025].
National Comprehensive Cancer Network. NCCN Guidelines Insights: Breast Cancer Version 4.2023. Available at: https://jnccn.org/view/journals/jnccn/21/6/article-p594.xml [Accessed March 2025].
National Comprehensive Cancer Network. Breast Cancer Guidelines Version 1.2025. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419 [Accessed March 2025].
National Comprehensive Cancer Network. Development and Update of Guidelines. Available at: https://www.nccn.org/guidelines/guidelines-process/development-and-update-of-guidelines [Accessed March 2025].
UK | March 2025 | 442295
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.